Mylan (NASDAQ:MYL) insider Anthony Mauro sold 12,257 shares of the company’s stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $40.35, for a total value of $494,569.95. Following the sale, the insider now directly owns 147,435 shares in the company, valued at $5,949,002.25. The transaction was disclosed in a filing with the SEC, which is available at this link.
Mylan (MYL) traded down $0.33 during trading hours on Wednesday, hitting $42.02. The stock had a trading volume of 3,160,000 shares, compared to its average volume of 5,560,000. Mylan has a 12 month low of $29.39 and a 12 month high of $47.82. The company has a market capitalization of $21,800.00, a PE ratio of 32.32, a price-to-earnings-growth ratio of 1.36 and a beta of 1.35. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.73 and a current ratio of 1.13.
Mylan (NASDAQ:MYL) last announced its earnings results on Wednesday, February 28th. The company reported $1.43 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.41 by $0.02. Mylan had a return on equity of 19.14% and a net margin of 5.84%. The business had revenue of $3.24 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter last year, the business posted $1.57 earnings per share. The company’s quarterly revenue was down .9% on a year-over-year basis. equities analysts expect that Mylan will post 5.38 EPS for the current fiscal year.
Several equities research analysts have weighed in on the company. Cantor Fitzgerald set a $34.00 target price on Mylan and gave the stock a “hold” rating in a research report on Thursday, November 30th. ValuEngine raised Mylan from a “hold” rating to a “buy” rating in a research report on Friday, December 1st. UBS Group set a $46.00 target price on Mylan and gave the stock a “buy” rating in a research report on Monday, December 4th. Guggenheim assumed coverage on Mylan in a research report on Tuesday, December 12th. They issued a “buy” rating and a $59.00 target price on the stock. Finally, BidaskClub raised Mylan from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 19th. Nine equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $45.92.
TRADEMARK VIOLATION NOTICE: This report was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://stocknewstimes.com/2018/03/14/mylan-myl-insider-anthony-mauro-sells-12257-shares-of-stock.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.